Galderma-backed trial shows Restylane Skinboosters-first, then Sculptra lifts facial dermal thickness 27.3% in menopausal women

• Galderma disclosed results from an eight-month investigator-initiated trial in menopausal women using Restylane Skinboosters with Sculptra on face, décolletage.
• The study found the combination improved hydration, skin quality, remodeling, sustained benefits, with high patient satisfaction reported.
• Sequencing mattered, with Skinboosters used first delivering faster visible improvement and stronger overall remodeling versus the reverse order.
• The data support a defined injectable protocol aimed at menopause-related skin changes, a potential demand driver for both products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galderma Group AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261012641517) on October 13, 2026, and is solely responsible for the information contained therein.